Companies Reap the Swine Flu Windfall

By Julie Steenhuysen – Analysis

CHICAGO (Reuters) – Healthcare companies are reaping the benefits of a global swine flu pandemic, brightening what might otherwise have been a dismal third quarter and bringing new focus on the market for vaccines.

Large European pharmaceutical companies are reporting windfall sales from flu drugs and H1N1 vaccines.

Small biotechs are winning fresh attention from investors and governments looking for quick, less expensive ways of making flu vaccines to protect their populations. And diagnostic companies have been growing revenues as doctors order more flu tests.

Go to full article.

, , ,

More in Big Pharma, H1N1, Health Care
Finance Committee Health Care Bill Has Been Filed

From Politico: Senate Finance Committee members have been notified that the committee's health reform bill was filed today. S. 1796 weighs in at 1,502 pages, according to a Senate Republican leadership...